Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of PF-07328948 in Adults With Renal Impairment and Healthy Participants
NCT07315360Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07328948 (3 arms), sponsored by Pfizer. Primary endpoints: Fraction of Unbound Drug in Plasma at 120 hours, Unbound Area Under the Curve from Time Zero to Infinity at 120 hours and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
PF-07328948
Beyond the preview
Go deeper on NCT07315360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315360.